research use only
Cat.No.S4030
| Related Targets | HDAC PARP ATM/ATR DNA-PK WRN Topoisomerase PPAR Sirtuin Casein Kinase eIF |
|---|---|
| Other DNA/RNA Synthesis Inhibitors | CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) RK-33 EED226 BMH-21 Carmofur Triapine (3-AP) YK-4-279 Halofuginone |
|
In vitro |
Water : 100 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | Formula | H2SO4.xUnspecified |
Storage (From the date of receipt) | ||
|---|---|---|---|---|---|
| CAS No. | 1405-41-0 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | NSC-82261, SCH9724 | SMILES | CCN.CNC(C)C.CNC1C(O)C(OCC1(C)O)OC2C(N)CC(N)C(OC3OC(CCC3N)[R])C2O.CC(C)N.O[S](O)(=O)=O | ||
Read more about storage stability stock solution CAS number SMILES
| In vitro |
Gentamycin Sulfate is a complex of three different closely related aminoglycoside sulfates, Gentamicins c1, c1a and c2, obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. Gentamycin Sulfate is reported to have activity against gram-negative bacteria, Pseudomonas aeruginosa, gram-positive Staphylococcus aureus and some mycoplasmas. Reported to have low toxicity to mammalian cells and viruses at certain concentrations, useful for long-term tissue culture studies with viruses. Gentamicin acts by binding to the 30S subunit of the bacterial ribosome leading to inhibition of protein synthesis and death in susceptible bacteria.
|
References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2023-08-04)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05977400 | NOT_YET_RECRUITING | Premature Birth; Antibiotics; Neurodevelopment |
Sharp HealthCare |
2024-04 | PHASE3 |
| NCT07752849 | RECRUITING | Cleft Palate; Unilateral Cleft Palate; Bilateral Cleft Palate; Complete Cleft Palat; Incompelet Cleft Palate |
Al-Thawra Modern General Hospital |
2026-08-01 | |
| NCT06712641 | RECRUITING | Sepsis |
University Hospital, Akershus |
2026-04-23 | PHASE4 |
| NCT04876131 | RECRUITING | Complicated Urinary Tract Infection; Infection; Pediatric Infectious Disease |
Murdoch Childrens Research Institute |
2022-05-30 | PHASE4 |
| NCT05157126 | RECRUITING | Fracture Open Tibia |
University of California, San Francisco |
2022-09-01 | PHASE4 |
| NCT06814223 | RECRUITING | Infection Catheter-Related |
Western Galilee Hospital-Nahariya |
2024-10-28 | PHASE4 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.